Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BofA Securities Downgrades BeyondSpring to Underperform from Buy, Adjusts Price Target to $5 from $45

12/02/2021 | 12:41pm EDT


© MT Newswires 2021
All news about BEYONDSPRING INC.
09/19BeyondSpring Inc.(NasdaqCM:BYSI) dropped from S&P Global BMI ..
CI
09/13BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Mon..
AQ
09/13BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyt..
CI
08/31North American Morning Briefing: Stocks Look to -2-
DJ
08/29BeyondSpring Inc. Announces Board Appointments
CI
08/29BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease ..
AQ
08/29BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease ..
CI
08/17North American Morning Briefing: Investors Seek -2-
DJ
08/10North American Morning Briefing: Caution -2-
DJ
07/27North American Morning Briefing: Growth Stocks -2-
DJ
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2022 0,70 M - -
Net income 2022 -49,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,83x
Yield 2022 -
Capitalization 38,0 M 38,0 M -
Capi. / Sales 2022 54,4x
Capi. / Sales 2023 28,2x
Nbr of Employees 103
Free-Float 47,6%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 0,98 $
Average target price 2,30 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Matthew Kirkby Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-78.48%38
GILEAD SCIENCES, INC.-13.74%78 498
REGENERON PHARMACEUTICALS, INC.10.05%74 302
VERTEX PHARMACEUTICALS29.66%73 024
BIONTECH SE-49.46%31 665
WUXI APPTEC CO., LTD.-40.29%29 141